Veranex Acquires Preclinical Science Firm IMMR

The shopping spree continues for Veranex.

The company formed last June has purchased IMMR, a French preclinical science organization that provides preclinical research, pathology evaluation and surgical training services to medical technology innovators. Financial terms of the deal were not disclosed. 

“We are excited to welcome IMMR to Veranex,” said Patrick K. Donnelly, executive chairman at Veranex. “Veranex is focused on the needs of the MedTech industry and this acquisition enhances our long-term ability to meet the end-to-end needs of medtech companies in one organization. Veranex’s clients will benefit from IMMR’s 30-plus years of experience in the design and conduct of preclinical studies, expertise in complex cardiovascular and non-cardiovascular procedures, and state-of-the art surgical suites and husbandry facilities, all unparalleled for leading successful completion of sophisticated studies with novel interventional or surgical technologies.”
 
Formed in June 2021 with global growth investor Summit Partners, Veranex provides the global medical technology industry with integrated solutions and services that accelerate the product life cycle to help improve the lives of patients everywhere. As a result of this acquisition, Veranex gains state-of-the-art, U.S. Food and Drug Administration-inspected and AAALAC-acredited facilities and extensive in-house expertise, enhancing Veranex’s services for preclinical studies worldwide.   
 
“As part of a combined company with a full range of product development, regulatory, and market access expertise, our partnership with Veranex complements our vision to help clients achieve their objectives and advance important medtech innovations that significantly improve patient care,” said IMMR Founding Partner and Scientific Director Luc Behr, D.V.M., Ph.D. “IMMR adds another dimension of expertise and services to Veranex to enable and accelerate research in the industry.”
 
IMMR’s full service approach—with studies that are carefully planned, expertly conducted to the highest ethical standards, and professionally documented—saves money and reduces time to market.
 
“IMMR excels in procedures ranging from early feasibility studies through to GLP studies to support global regulatory approvals,” added IMMR Founding Partner and Scientific Director Nicolas Borenstein, D.V.M., Ph.D. “With our expert team of professionals, our worldwide clientele enjoys high success rates with their medical technology innovations.”
 
Clearwater International and Cain Brothers served as financial advisors for the acquisition while international law firm Gide Loyrette Nouel acted as legal counsel. 
 
Veranex is a global, tech-enabled service provider dedicated to the medical technology industry. Offering expert guidance from concept through to commercialization and across the development continuum, Veranex enables accelerated speed to market, controlled development costs, development risk mitigation, and accelerated market viability assessment.